Competition Policy
An official website of the European Union An official EU website
Skip to main content
Competition Policy logo
Competition Policy

Competition Policy

AT.40394 Aspen

Economic Activity: C.21.2 - Manufacture of pharmaceutical preparations
Date Document Type Document
03.05.2021 Trustee contact details published on 03.05.2021
10.02.2021 Commitments Decision published on 15.04.2021
10.02.2021 Final commitments published on 10.02.2021
10.02.2021 Press Release Commission accepts commitments by Aspen to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns :
10.02.2021 Summary Decision Summary of Commission decision - OJ_C_2021_435_FULL_EN_TXT :
05.02.2021 Opinion of the Advisory Committee Advisory Committee report - OJ_C_2021_435_FULL_EN_TXT :
05.02.2021 Report of the Hearing Officer Hearing Officer report - OJ_C_2021_435_FULL_EN_TXT :
15.07.2020 Market Test Notice (Art. 27(4)) Market Test Notice (Art. 27(4)) :
14.07.2020 Memo Antitrust: Aspen proposes 73% price reduction for six off-patent cancer medicines to remove Commission's excessive pricing concerns-Fact sheet :
14.07.2020 Press Release Anitrust: Commission seeks feedback on commitments offered by Aspen to reduce prices for six off-patent cancer medicines by 73% to address Commission’s concerns over excessive pricing :
14.07.2020 Proposed Commitments published on 14.07.2020
15.05.2017 Opening of Proceedings published on 31.05.2017
15.05.2017 Press Release Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines :
These publications are for information purposes only and should not be considered as an official publication

New Search